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Capsule 
Background: Glutaredoxin-1 (Glrx) inhibits 
endothelial cell migration by reversing protein-
glutathione adducts. 
Results: Revascularization after hind-limb 
ischemia was inhibited in Glrx transgenic mice. 
Glrx overexpression increased soluble VEGF 
receptor 1 (sFlt) in endothelial cells via NF-kB-
dependent Wnt5a production. 
Conclusion: Glrx enhances Wnt5a-induced anti-
angiogenic sFlt in endothelial cells. 
Significance: Up-regulated Glrx inhibits VEGF 
signaling by increased sFlt causing impaired 
vascularization. 
 
Abstract 
Glutaredoxin-1 (Glrx) is a cytosolic enzyme that 
regulates diverse cellular function by removal of 
GSH adducts from S-glutathionylated proteins 
including signaling molecules and transcription 
factors. Glrx is up-regulated during inflammation 
and diabetes. Glrx overexpression inhibits VEGF-
induced endothelial cell (EC) migration. The aim 
was to investigate the role of up-regulated Glrx in 
EC angiogenic capacities and in vivo 
revascularization in the setting of hind limb 
ischemia. Glrx overexpressing EC from Glrx 
transgenic mice (TG) showed impaired migration 
and network formation and secreted higher level 
of soluble VEGF receptor 1 (sFlt), an antagonizing 
factor to VEGF. After hind limb ischemia surgery   
Glrx TG mice demonstrated impaired blood flow 
recovery, associated with lower capillary density 
and poorer limb motor function compared to wild 
type littermates. There were also higher levels of 
anti-angiogenic sFlt expression in the muscle and 
plasma of Glrx TG mice after surgery. Non-
canonical Wnt5a is known to induce sFlt. Wnt5a 
was highly expressed in ischemic muscles and EC 
from Glrx TG mice, and exogenous Wnt5a 
induced sFlt expression and inhibited network 
formation in human microvascular EC.  
Adenoviral Glrx-induced sFlt in EC was inhibited 
by a competitive Wnt5a inhibitor. Furthermore, 
Glrx overexpression removed GSH adducts on p65 
in ischemic muscle and EC, and enhanced nuclear 
factor kappa B (NF-kB) activity which was 
responsible for Wnt5a-sFlt induction. Taken 
together, up-regulated Glrx induces sFlt in EC via 
NF-kB -dependent Wnt5a, resulting in attenuated 
revascularization in hind limb ischemia. The Glrx-
induced sFlt may be a part of mechanism of redox 
regulated VEGF signaling. 
Introduction 
Excess levels of reactive oxygen and nitrogen 
species (RONS) contribute to various pathological 
conditions. However, physiological levels of 
RONS are also essential for cellular signaling in 
part through modification of redox sensitive 
cysteine thiols on proteins. Exposure of reactive 
cysteine thiols to RONS in the presence of 
glutathione (GSH) results in S-glutathionylation, a 
reversible post-translational modification. GSH 
adducts may provide signaling mechanism and 
protect proteins from irreversible oxidation during 
fluctuations of RONS levels (1). This reversible 
modification can result in functional inhibition (2–
4) or activation (5, 6) of a broad range of proteins 
with redox-sensitive thiols. Thus, regulation of 
GSH adducts has significance in various clinical 
conditions (7). Glutaredoxin-1 (Glrx) is a cytosolic 
enzyme that specifically catalyzes the removal of 
GSH adducts from S-glutathionylated proteins (P-
SSG) (8). Therefore, Glrx can regulate cellular 
functions including signal transduction, 
cytoskeleton dynamics, and gene transcription by 
reversing S-glutathionylation (9, 10). A well-
studied example is the NF-kB pathway wherein 
GSH adducts inactivate inhibitor of kappa B 
kinase (IKK) and inhibit DNA binding of p50 
(11) and p65 (12) subunits, thus Glrx promotes 
NF-kB activation by removing GSH adducts (7, 
13, 14). Glrx expression is increased in 
atherosclerotic human coronary artery (15), 
allergic mouse airway (16), and diabetic rat retina 
(13). Plasma Glrx activity is increased in type 2 
diabetic patients (17), suggesting an association 
with oxidative stress. However, because GSH 
adducts have various effects on protein function, 
the cellular effects of increased Glrx are more 
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complex than that of an antioxidant enzyme, and 
may differ depending on tissue and pathological 
conditions. 
Vascular endothelial growth factor A (VEGF) is 
a major factor to stimulate arteriogenesis and 
angiogenesis. VEGF binds VEGF receptor 2 
(VEGFR2; Kdr/Flk1) resulting in receptor 
dimerization and phosphorylation of tyrosine 
residues. VEGFR2 is the main transducer of 
VEGF on endothelial proliferation, migration, and 
network formation (18). However, VEGF binds to 
VEGFR1 (fms-like tyrosine kinase-1; Flt) with 
higher affinity than VEGFR2. Flt can function as a 
negative regulator for VEGFR2 since a full-length 
membrane-tethered Flt (mFlt) transduces a weaker 
signal than VEGFR2, and a soluble splice variant 
(sFlt) can capture the VEGF ligand as a decoy to 
prevent its binding to VEGFR2 (18, 19). A 
number of redox-sensitive proteins are involved in 
VEGF signaling (20). S-glutathionylation 
inactivates protein tyrosine phosphatases (4, 21) 
and thus promotes tyrosine phosphorylation of 
VEGF receptor and signaling.  
We previously observed that Glrx 
overexpression inhibited endothelial angiogenic 
properties in vitro (22). In contrast, a report 
suggests Glrx overexpression may be beneficial 
for recover of cardiac dysfunction after ischemia 
(23). Therefore, we dissected the mechanism in 
which Glrx inhibits EC migration and examined 
whether Glrx up-regulation in vivo may improve 
or inhibit post-ischemic revascularization using 
Glrx overexpressing mice.  The overexpression of 
Glrx was similar to the increase in enzyme activity 
observed in the onset of diseases such as diabetes.  
As a result, we found that Glrx overexpressing 
EC produced higher level of anti-angiogenic sFlt, 
and inhibiting sFlt expression reversed the anti-
angiogenic effects of Glrx in EC. In vivo, the 
blood flow recovery after femoral artery ligation 
was significantly impaired in association with 
poorer motor function in Glrx transgenic (TG) 
mice compared to WT mice.  Interestingly, plasma 
levels of the inhibitory VEGF receptor sFlt were 
higher in the Glrx TG mice. Accordingly, we 
found that Glrx overexpression up-regulated non-
canonical Wnt ligand, Wnt5a (wingless-type 
MMTV integration site family, member 5A) in 
ischemic muscle and cultured endothelial cells. 
Wnt5a in myeloid cells was shown to inhibit post-
natal angiogenesis through Flt induction (24). 
Wnt5a activates NF-kB via -catenin-independent 
signaling in endothelial cells (25), while 
inflammatory stimuli induce Wnt5a via NF-kB 
activation in monocytes (26, 27). We showed that 
exogenous Wnt5a treatment increased sFlt 
expression in EC and inhibited endothelial 
network formation. Our data indicate that Wnt5a 
regulates sFlt in endothelial cells in an 
autocrine/paracrine fashion, and Glrx up-
regulation enhanced the Wnt5a-sFlt pathway, in 
part through NF-kB activation, and resulted in 
inhibition of in vivo revascularization in hind-limb 
ischemia. 
MATERIALS AND METHODS 
Mouse Hind limb ischemia (HLI) model—
Animal study protocols were approved by the 
Institutional Animal Care and Use Committee at 
Boston University. Glrx TG mice were generated 
with Human Glrx overexpression driven by the 
human β-actin promoter at the laboratory of Dr. 
YS. Ho (Wayne State University, Detroit) (23). 
Heterozygote Glrx TG mice and wild-type (WT) 
littermates, male 8-9 month old, were subjected to 
unilateral HLI by surgical excising left femoral 
artery and vein as previously described (28, 29). 
Blood flow measurements and the functional 
scores—Blood flow perfusion was measured by 
LASER Doppler (Moor Instruments UK) on 
plantar aspects of the feet of anesthetized mice ( 
ketamine (100mg/kg) xylazine (10mg/kg); i.p.) as 
previously described (28). Severity of the ischemia 
was scored by assessment of limb function and 
mobility. Using the following criteria under 
blinded conditions; 1. No use of limb, 2. No use of 
foot, 3. Dragging of foot, 4. No toe spreading, 5. 
Full use of foot. Limb function of all mice was 
scored at the same time as blood flow 
measurements prior to sedation. Functional agility 
was measured on day 10 post-surgery by running 
on a treadmill until exhaustion. 
Histological assessment—Capillary density was 
quantified in non-ischemic and ischemic 
gastrocnemius muscle by histological assessment, 
by isolectin B4 (Vector labs) staining. 
ELISA—Murine VEGF-A and soluble VEGFR1 
ELISA (R&D Systems) were performed on plasma 
from WT and Glrx TG mice and media collected 
from endothelial cells. 
Anti-angiogenic soluble Flt induction by glutaredoxin-1 
4 
 
Aortic sprouting assay—Aortic rings from WT 
and Glrx TG mice were placed on growth factor-
reduced Matrigel (BD Bioscience) supplemented 
with DMEM, 2% FBS and 1% penicillin/ 
streptomycin. Experiments were conducted using 
4 mice from each group and 4-5 rings per mouse 
and area of outgrowth was measured using 
ImageJ. 
Isolation of mouse endothelial cells—
Microvascular ECs were selectively (CD31, BD 
Pharmagin) isolated from heart from WT and Glrx 
TG mice using a Macs Automated Cell Sorter 
(Miltenyi Biotec) after digestion in 
gentleMACSTM Dissociator (Miltenyi Biotec). 
Endothelial cell network formation—Quiescent 
ECs were seeded (1x104 cells /well) in 96-well 
plates coated with Matrigel (growth factor 
reduced; BD Biosciences). Network formation was 
assessed after treatment with or without VEGF 
(50ng/ml) in low serum endothelial growth media 
(Lonza) (22). Network formation was scored or 
length measured in a blinded manner as previously 
described (30). 
Endothelial proliferation—Quiescent ECs were 
seeded (1x104 cells /well) in gelatin coated 96-well 
plates. After 24 hours EC proliferation was 
measured in the presence and absence of VEGF 
(50ng/ml) in EBM2 media with 0.5% FBS using 
cell proliferation kit (Biovision). 
Endothelial cell migration—As previously 
described (30), EC migration was measured in the 
presence and absence of VEGF (50ng/ml) after 
performing scratch in a confluent monolayer of 
WT and TG mECs. Migration was quantified at 
four defined locations by measuring the area of the 
scratch per well at 0 and 18h using ImageJ. 
Glutaredoxin activity assay—Glrx activity in 
muscle homogenate was determined by the 
NADPH dependent reduction of 2-
hydroxyethildisulfide (HED) (31). 
Glrx adenoviral overexpression—Adenovirus 
expressing human Glrx was a generous gift from 
Dr. Young J. Lee (University of Pittsburgh) (32) 
and it has been used in previous reports (22, 33). 
Human cardiac microvascular endothelial cells 
(hEC, Lonza) were infected in FBS-free EBM2 
media with Glrx or -galactosidase (LacZ) 
(control) adenoviruses with 10 g/ml Polybrene™ 
(Sigma) and subsequently used for 72 hours. 
siRNA in hECs—After adenoviral 
overexpression of LacZ or Glrx, p65 knockdown 
was achieved using on-target plus siRNA  
(Dharmacon). hEC were transfected with siRNA 
against p65 (200 pmol; Dharmacon) or non-
silencing control using Lipofectamine™ 2000 
reagent (Invitrogen) following manufacturer 
instructions. Cells were used in experiments 48-72 
hours after transfection. Specific knockdown of 
sFLT was achieved by targeting two siRNA 
sequences to the unique 3’ sequence of sFLT 
(Dharmacon siGENOME) as previously reported 
(34). 
qRT-PCR—Total RNA was isolated from tissues 
or cells using TRIzol™ reagent (Invitrogen) and 
cDNA generated utilizing High Capacity RNA-to-
cDNA kit (Invitrogen). Quantitative PCR was 
conducted using inventory mouse (Mm) and 
human (Hs); gene-specific TaqMan™ primers 
(Life Technologies):   Glrx (Mm00728386_m1), 
(Hs00829752_g1); Wnt5a (Mm00437347_m1), 
(Hs00998537_m1); mFLT (Mm00438980_m1); 
VEGFA (Mm01281449_m1), (Hs0090055_m1); 
Flk/KDR (Mm00440111_m1), (Hs00911700_m1); 
Ror2 (Mm00443470_m1); E-selectin 
(Hs00950401_m1); IL6 (Hs00985639_m1);-
actin; mouse (4352933), human (4326315). 
Expression was obtained and analyzed using 
comparative Ct (ΔΔCT) with StepOne™ Real 
Time PCR software (Applied Biosystems), 
normalized to -actin. The sequence for the 
custom designed TaqMan™ assay to assess human 
sFlt transcript was kindly provided by Dr. Stefanie 
Dimmeler (35). SYBR green primers were used to 
assess murine mFlt and sFlt according to the 
transcripts as published (24). 
NF-kB luciferase activity assay—NF-kB reporter 
activity in WT and Glrx TG mEC was assessed by 
co-transfection with pNF-kB-LUC reporter and 
Renilla luciferase adenoviruses. The EC were 
stimulated with TNF (100ng/ml, Sigma) for 4h 
and subsequent dual luciferase for Firefly 
luciferase and Renilla luciferase (Promega) 
activity was measured using a Tecan luminometer. 
The NF-kB luciferase activity was normalized to 
the Renilla luciferase activity (NF-kB/Renilla 
luciferase activity). 
Hypoxia—Endothelial cells in EBM2 with 0.1% 
FBS were incubated at 0.5% or 0.1% O2, 70% 
humidity at 37ºC in a hypoxia chamber (Pathology 
Devices, Inc.) for 20 hours prior to isolation for 
biotin switch assay. 
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Biotin switch assay—S-glutathionylation of p65 
was assessed as previously described (30, 36), 
hECs were lysed with maleimide (100mol/L) to 
block free cysteines.  Modified thiols were 
reduced with DTT (20mM) and subsequently 
labeled with biotin-HPDP (N-[6-(biotinamido) 
hexyl]-3'-(2'-pyridyldithio) propionamide) 
(Peirce). Biotinylated proteins were purified with 
magnetic streptavidin agarose beads (Pierce) and 
biotin-HPDP modified proteins were 
immunoblotted with anti-p65 antibody (Cell 
Signaling). 
Reagents—Reagents were obtained as follows; 
Recombinant Wnt5a (RD systems), Wnt5a 
antagonist Box5 (Millipore), rat-anti-Wnt5a 
antibody (RD systems). Human and mouse Glrx 
antibodies were custom ordered by Bethyl 
Laboratories, Inc. 
Statistical Analysis—All group data are reported 
as mean ± SEM except as otherwise indicated.  
For the experimental data, statistical analysis 
comparing two groups was carried out using 
Student’s unpaired t-test. Analysis of more than 
two groups was performed either by One-way 
ANOVA or Two-way ANOVA followed by 
Tukey post-hoc comparison test. Sequential 
measurements were analyzed by repeated measure 
one-way ANOVA. Analyses were completed 
using GraphPad Prism v5.0. P values <0.05 were 
considered significant. 
RESULTS 
 VEGF-induced migration and network formation 
diminished in Glrx TG endothelial cells—To 
understand the functional significance of 
endothelial Glrx on angiogenic function, we 
explored the function of Glrx overexpressing 
endothelial cell in vitro and ex vivo. Microvascular 
endothelial cells (Cd31+) were selectively isolated 
from WT and Glrx TG hearts. Human Glrx 
expression was confirmed in Glrx TG mouse 
microvascular endothelial cells (mEC), and there 
was no change in endogenous Glrx expression 
between WT and Glrx TG mECs (Figure 1A). 
Furthermore, we assessed mEC network formation 
and migration. VEGF-induced network formation 
of mEC seeded on Matrigel was significantly 
inhibited in Glrx TG compared to WT mEC 
(Figure 1B&C). VEGF-induced migration was 
also attenuated in Glrx TG mEC (Figure 1D&E). 
In addition, mouse aorta rings were cultured ex 
vivo on Matrigel to assess endothelial sprouting. 
VEGF (50 ng/ml)-induced sprouting was 
attenuated in Glrx TG aortae compared to WT 
(Figure 1F&G). Together these data indicate 
VEGF-induced angiogenic function was impaired 
in Glrx TG derived endothelial cells. 
 Soluble Flt isoform was induced by Glrx 
overexpression—Alternative splicing of the anti-
angiogenic Flt gene results in the membrane 
anchored isoform (mFlt) and a soluble isoform 
that is secreted extracellularly (sFlt). In seeking a 
mechanism for decreased angiogenic behavior of 
Glrx TG EC, we used primers specific for 
different Flt isoforms and found both sFlt and mFlt 
mRNA expression were increased in mEC isolated 
from Glrx TG mice compared to cells from WT 
control (Figure 2A&B).  Hypoxia induces sFLT 
expression in ECs.   After 24 hours hypoxic 
treatment, sFlt and mFlt expression remained 
significantly higher in TG ECs. To determine if 
EC could secrete sFlt, we collected media (after 
24h quiescence) from mEC isolated from Glrx TG 
and WT mice under normoxic and hypoxia 
conditions.  sFlt levels were markedly greater in 
media from Glrx TG mEC compared to WT mEC. 
Interestingly a marked increase was observed with 
hypoxic treatment in TG mECs (Figure 2C). 
 Inhibiting sFlt reverses the anti-angiogenic effect 
of Glrx—In order to elucidate the contribution of 
sFlt in the anti-angiogenic role of Glrx, we 
specifically knocked-down sFlt in human ECs 
using siRNA designed to target the unique C-
terminal region of the sFlt isoform as previously 
reported in human endothelial cells (34).  
In order to be able to utilize the reported sFLT 
siRNA we used human microvascular endothelial 
cells (hEC) and induced Glrx overexpression by 
adenoviral infection. Glrx adenoviral 
overexpression in human EC (22) caused the same 
phenotype we observed in microvascular EC 
isolated from Glrx mice, i.e. inhibition of 
migration and network formation. Quantitative 
PCR showed significant suppression of sFlt 
mRNA with siRNA for sFlt (Figure 2D). 
Proliferation was decreased in ECs overexpressing 
Glrx, however knockdown of sFlt reinstated the 
level of proliferation observed in LacZ treated ECs 
(Figure 2E). Likewise, sFlt knockdown rescued 
Glrx-induced attenuation of EC migration (Figure 
2F&G). Furthermore, EC network formation that 
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was inhibited by Glrx overexpression was reversed 
with sFlt knockdown (Figure 2H&I). Together 
these data confirm that Glrx inhibits endothelial 
function through sFlt. 
 Wnt5a is increased by Glrx overexpression and 
regulates sFlt in EC—It has recently been 
reported that Wnt5a inhibits developmental 
angiogenesis through Flt regulation in myeloid 
cells (24). Therefore, we investigated whether 
Glrx increased sFlt via Wnt5a induction. Wnt5a 
expression was increased in mECs isolated from 
Glrx TG mice (Figure 3A). In addition, receptor 
tyrosine kinase-like orphan receptor 2 (Ror2), a 
receptor for the Wnt5a ligand (37) was also up-
regulated in Glrx TG  mECs (Figure 3B). To 
explore the control of sFlt expression further, hEC 
were treated with recombinant Wnt5a. Wnt5a (100 
ng/ml) induced a marked but transient increase in 
mRNA expression of sFlt and mFlt within 3 hrs 
(Figure 3C&D). Next, EC network formation and 
migration were evaluated in response to Wnt5a 
treatment.  After 24 h incubation with Wnt5a, 
human endothelial network formation was 
inhibited (Figure 3E&F) similar to the 
observations in Glrx TG mEC. Interestingly, Glrx 
overexpression in hEC resulted in increased 
Wnt5a mRNA expression, which was associated 
with increased sFlt expression (Figure 3G&H). To 
determine the role of Wnt5a on the expression of 
sFlt in these cells, the Wnt5a competitive 
antagonist, Box5 was utilized to block non-
canonical Wnt5a signalling (38). hEC infected 
with Glrx or LacZ were treated with or without 
Box5 (100µM, 18h). Box5 prevented Glrx-
induced sFlt expression in hEC (Figure 3I). 
Together, our data indicate that Wnt5a increases 
sFlt in human endothelial cells as shown 
previously in myeloid cells (24) and confirm that 
Glrx induces sFlt via Wnt5a in EC. 
 Glrx overexpression impairs in vivo blood 
recovery after femoral artery ligation —To 
investigate the in vivo role of Glrx up-regulation 
on post-ischemia re-vascularization, Glrx TG mice 
were utilized in which overexpression of the 
human Glrx transgene was achieved by the β-actin 
promoter (Figure 4A). (27). Expression of the 
human Glrx observed in TG gastrocnemius muscle 
had no effect on endogenous Glrx expression as 
murine Glrx protein was similar between Glrx TG 
and WT mice (Figure 4B). The additional Glrx 
expression from transgene resulted in a significant 
3-fold increase in Glrx activity in the TG muscle 
and heart homogenate compared with WT 
homogenate (Figure 4C) which was similar level 
of increase in Glrx activity observed in diabetic 
animals (13). Hind limb ischemic blood flow 
recovery was compared in Glrx TG mice to WT 
littermate controls. Blood flow was assessed 
serially after HLI surgery (day 0, 3, 7 and 14) by 
LASER Doppler speckle tracking in the plantar 
aspect of the paws (Figure 4E). In WT mice blood 
flow recovery was evident on day 3, whereas Glrx 
TG blood flow was consistently lower over the 2-
week measurement period (Figure 4D&E, P<0.05, 
repeated measured ANOVA). Glrx TG mice often 
had a necrotic toes and feet (Figure 4F). The 
functional impact of impaired revascularization 
was assessed by examining ambulatory foot 
movement. Scoring of motor function showed 
Glrx TG mice were less able to use the ischemic 
limb, whereas WT mice generally had full use of 
the limb and their toes had grip reflex 7 days after 
the surgery (Figure 4G). To further examine the 
consequence of ischemia on limb motor function, 
mice were placed on a treadmill and exercise 
function was assessed by calculating the time 
required to run until exhaustion (akin to the 
clinical walk test conducted on peripheral artery 
disease patients). Ten days after surgery Glrx TG 
mice showed impairment of limb function as they 
ran for a shorter time period compared to WT 
mice (Figure 4H). As blood flow recovery in part 
corresponds to increased tissue capillary density, 
we examined the capillary density in 
gastrocnemius muscle. As expected, in WT mice, 
capillary density increased in the ischemic 
gastrocnemius muscle, however in the ischemic 
Glrx TG muscle there was a marked attenuation of 
the capillary increase (Figure 4I&J). There was no 
significant difference in capillary density in non-
ischemic limbs. 
 Soluble Flt expression is increased in Glrx TG 
mouse muscle and plasma—In accordance with 
the increase in sFlt in Glrx overexpressing EC, we 
found both sFlt and mFlt mRNA expression were 
higher in Glrx TG ischemic muscle compared to 
WT control 14-days after HLI surgery (Figure 
5A&B), whereas no difference was observed in 
VEGF and VEGFR2 expression (Figure 5C&D). 
Furthermore, the level of sFlt, assessed by ELISA 
was significantly higher in plasma from Glrx TG 
mice on both 4 and 14 days post-HLI (Figure 5E). 
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We analyzed VEGF levels in mouse plasma 4 and 
14 days after the HLI surgery by ELISA and found 
no difference in circulating VEGF levels (Figure 
5F). Interestingly, Wnt5a expression was 
markedly increased in Glrx TG ischemic muscle 
compared to WT. In contrast, Wnt5a levels were 
low in non-ischemic limb from both WT and Glrx 
TG mice (Figure 5G). These data suggest that 
Wnt5a and sFlt induction in Glrx overexpressing 
EC might occur in Glrx TG mice.  
 Glrx removes p65-NF-kB GSH adducts in 
ischemic muscle and EC—We used a biotin switch 
assay to quantify reversible cysteine 
modifications. This assay first irreversibly blocks 
free cysteines, and then selectively labels 
reversible cysteine modifications with biotin-
HPDP after reduction with DTT. The HPDP 
modified proteins are then precipitated with 
streptavidin and blotted for the protein of interest 
to indicate the level of thiol modification of that 
protein. Interestingly, we found that thiol adducts 
on p65 were increased in the ischemic muscle of 
WT mice (Figure 6A&B), but were significantly 
attenuated in that of Glrx TG mice, consistent with 
a decrease in GSH adducts. This also indicates 
significantly higher Glrx activity (removing GSH 
adducts) in vivo in Glrx TG mice. Thus, 
confirming that the modest increase observed in 
Glrx activity (Figure 4C) has an in vivo biological 
consequence. We also found that adenoviral 
overexpression of Glrx lowered GSH adducts of 
p65 compared to LacZ infected EC (Figure 6C). 
Furthermore, Glrx overexpression prevented the 
increase in GSH adducts on p65 under hypoxia 
(0.1%, 20h) (Figure 6C&D). 
Glrx enhances Wnt5a and sFlt in a NF-kB- 
dependent manner—To confirm that removal of 
glutathione adducts enhanced NF-kB activity in 
Glrx TG EC, an NF-kB-reporter assay was used in 
isolated mEC treated with TNFα, a well described 
NF-kB activator. TNFα stimulated greater NF-kB 
activity in Glrx TG mEC compared to WT mEC 
(Figure 7A). Next, we investigated whether the 
inhibition of NF-kB activity could prevent Glrx-
induced Wnt5a expression. We used human ECs 
overexpressing Glrx by adenovirus infection. First, 
hEC were treated with MG132, a proteasome 
inhibitor, which stabilizes IB and inhibits NF-
kB. MG132 prevented the transcriptional up-
regulation of Wnt5a by Glrx overexpression 
(Figure 7B). Likewise, we assessed if siRNA 
knockdown of p65 could prevent Wnt5a 
expression. SiRNA treatment was effective after 
72 hours, inhibiting p65 protein expression (Figure 
7C), and preventing TNFα-induced E-selectin 
(Figure 7D) and AdGlrx induced IL-6 expression 
(Figure 7E) which validate p65 knockdown 
inactivating NF-kB. Furthermore, siRNA 
knockdown of p65 attenuated the AdGlrx-induced 
increase in Wnt5a and sFlt observed in hECs 
(Figure 7F&G). AdGlrx expression had no effect 
on VEGFR2 expression, whereas p65 knockdown 
increased VEGFR2 expression (Figure 7H). 
Together these data indicate that induction of 
Wnt5a expression by Glrx is mediated via NF-kB 
activation, and promotes sFlt production in EC, 
summarized in Figure 8.  
DISCUSSION 
Glutathione adducts on redox-sensitive cysteine 
thiols are becoming increasingly recognized as an 
important mechanism for cellular signaling (39). 
Glrx specifically reverses protein-bound 
glutathione adducts, thus acting as a signaling 
switch on a range of important proteins (7, 40). 
Up-regulated Glrx under oxidative stress (e.g. 
ischemia) might accelerate turnover of GSH 
adducts, thus promoting pathological signaling. 
Our data reports for the first time that Glrx 
regulates anti-angiogenic sFlt production through 
the non-canonical Wnt5a pathway that may have 
important implications in ischemic vascular 
disease, as up-regulation of Glrx impaired 
ischemic limb revascularization. 
Up-regulated Glrx resulted in impaired ischemic 
limb revascularization and exercise function. In 
addition, capillary density in the ischemic muscle 
from Glrx mice was lower compared to WT mice. 
Interestingly, the alternative splice variant of 
VEGFR1 (Flt), sFlt was increased in plasma after 
HLI surgery from Glrx TG mice. In addition, we 
detected higher sFlt in the media of EC isolated 
from Glrx TG mice. VEGFR2 mainly transduces 
VEGF-induced angiogenic responses, while Flt 
negatively regulates angiogenic signals by 
sequestering VEGF with high affinity to prevent 
the ligand binding to VEGFR2, and the 
membrane-tethered Flt (mFlt) appears to have 
weaker tyrosine kinase activity than VEGFR2 in 
angiogenic signaling (18). Adenoviral sFlt gene 
transfer inhibited revascularization in murine HLI 
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(41). Elevated sFlt during pregnancy has been 
implicated in pre-eclampsia (42) and peripartum 
cardiomyopathy (43) by anti-angiogenic 
mechanisms. Soluble Flt expression was elevated 
in the serum of diabetic rats (44) and the ischemic 
muscle of diet-induced diabetic mice in 
association with impaired blood flow after femoral 
artery ligation (45). Glrx expression is associated 
with various disease processes. Glrx levels were 
shown to be higher in diabetic rat (13) and in 
plasma from diabetic patients (17). In this study 
we used mice that overexpressed Glrx to a similar 
degree to the pathological level (13). Our findings 
may help to explain why diabetic patients have 
poor revascularization capability and a higher 
incidence of vascular ischemia, intermittent 
claudication and lower limb amputations (45). 
Soluble Flt production is regulated by 
alternatively splicing (35), and ectodomain 
shedding of Flt by proteolytic cleavage has also 
been suggested as a mechanism of sFlt production 
in cancer cells (46). Using primers which 
distinguish the splice variants, we found that Glrx 
overexpression increased mFlt as well as sFlt in 
human and mouse EC. At this point, it is not clear 
whether splicing factors and/or ectodomain 
shedding are regulated by Glrx. VEGF gene 
expression and VEGF levels in plasma were not 
different by Glrx TG, and VEGFR2 expression 
was not altered by Glrx overexpression in EC. 
Previously, Stefater et al. reported that the non-
canonical Wnt ligand, Wnt5a, in myeloid cells 
inhibited postnatal angiogenesis by inducing sFlt 
(24). The importance of Wnt ligands as 
developmental regulators of cell proliferation, 
migration, differentiation, and polarity are well 
known. In addition, recent reports suggest 
inhibitory roles of myeloid derived Wnt5a in 
developmental angiogenesis and wound repair (24, 
47). Surprisingly, Wnt5a was highly expressed in 
ischemic hind limb muscle of Glrx TG compared 
to WT control. Also, Wnt5a expression was 
significantly higher in EC from Glrx TG mice, and 
Glrx overexpression increased Wnt5a as well as 
sFlt mRNA in human EC, suggesting that 
dysregulation of Wnt5a in the adult may have 
pathological significance. Recombinant Wnt5a 
induced sFlt in EC and inhibited EC network 
formation extending the previous finding in 
myeloid cells (24) to a different cell type. Ror2 is 
involved in non-canonical Wnt5a signaling and is 
a negative regulator of canonical Wnt/-catenin 
pathway (37, 48). Elevation of Wnt5a levels 
causes increases in Ror2 expression (49). We 
found that Ror2 expression was significantly 
higher in Glrx TG derived EC consistent with 
Wnt5a responsiveness being increased in Glrx TG 
mice. Furthermore, competitive Wnt5a inhibitor, 
Box5, blocked Glrx-induced sFlt mRNA in EC, 
suggesting Glrx-induced sFlt in EC is Wnt5a-
dependent. 
Wnt5a causes p65 nuclear translocation and 
inflammation in EC (25), but also Wnt5a can be 
induced via NF-kB activation in monocytes (26, 
27). As previously mentioned, Glrx promotes NF-
kB activation through reversing S-
glutathionylation of NF-kB components. We 
demonstrated higher TNF-induced NF-kB 
activity in Glrx overexpressing EC. Moreover, 
using a biotin switch assay we showed Glrx 
decreased reversible thiol modifications on p65 in 
ischemic muscle and EC. Specific DNA binding of 
NF-kB (p50, p65) is inhibited by GSH adducts 
(11, 12, 23). We speculate IKK and p50 might be 
S-glutathionylated as well and contribute to NF-kB 
activation by Glrx, although we were unable to 
show that by the biotin switch method. Inhibition 
of NF-kB by MG132 or siRNA to p65 blocked 
Wnt5a induction by Glrx overexpression. In 
addition, Glrx-induced sFlt was attenuated in EC 
through NF-kB inhibition. These data indicate that 
Glrx induced Wnt5a and sFlt is related to 
activation of NF-kB. Glrx expression itself is 
induced by NF-kB activity (50) and up-regulated 
by inflammation and diabetes (13), suggesting 
deleterious positive feedback of the Glrx-NF-kB-
Wnt5a pathway. In accordance with our data, 
inhibition of NF-kB with mutant IkB increased 
disorganized vasculature in ischemic mouse hind 
limb (51) and enhanced tumor growth (52), 
suggesting tight regulation of NF-kB is required to 
maintain normal vascularization (53). 
A recent report suggests that after coronary 
artery ligation, Glrx TG mice may have improved 
neovascularization and cardiac remodeling due to 
less apoptosis (23). In their report, they showed -
actin staining was increased in the heart and 
VEGF expression was elevated, which may be 
insufficient to conclude that Glrx TG promotes 
eovascularization in heart. Higher VEGF 
expression does not necessarily correlate with 
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angiogenesis (45). They also showed hyper-
activation of NF-kB that may contribute the 
protection of myocytes from apoptosis. Glrx may 
be protective in ischemic heart due to inhibition of 
apoptosis. We conducted a more extensive study 
on angiogenic properties in Glrx overexpressing 
EC and mice. Our results clearly demonstrated that 
up-regulated Glrx inhibits EC migration and 
network formation in vitro, and impairs hindlimb 
revascularization in vivo. 
In myeloid cells Wnt5a induction of sFlt is likely 
through nuclear factor of activated T cells (NFAT) 
activation (47). Interestingly, the interaction 
between NFAT and NF-kB p65 promotes 
synergistic activation of NFAT (54). Also, many 
transcription factors are known to be redox-
sensitive including AP-1/c-Jun (55), p53 (56),Nrf-
2 and its regulatory protein, Keap-1 (57). 
Therefore, other transcriptional regulation might 
be involved in Glrx-induced Wnt5a and sFlt. 
Furthermore, we assume there may be multiple 
Glrx targets involved in VEGF and angiogenesis 
signaling because many related proteins are known 
to be S-glutathionylated, such as SERCA (5), H-
Ras (33, 36), PTP1B (4), -actin (10, 58), eNOS 
(59), and sirtuin-1 (2), all of which could be 
involved. Further studies will elucidate redox-
sensitive regulation of sFlt induction. 
In summary, we report a novel pathway by 
which Glrx overexpression induces sFlt through 
increasing Wnt5a in EC, resulting in impaired in 
vivo revascularization after limb ischemia. In 
addition, we extended the importance of Wnt5a-
sFlt pathway to endothelial cells. These results are 
of significant importance because Glrx is up-
regulated in pathological conditions including 
diabetes in which ischemic conditions are 
worsened. 
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microvascular endothelial cells; hEC, human cardiac microvascular endothelial cells; HLI, hind limb 
ischemia; mFlt, membrane-bound VEGF receptor-1; RONS, reactive oxygen nitrogen species; Ror2, 
receptor tyrosine kinase-like orphan receptor 2; sFlt, soluble fms-like tyrosine kinase-1, VEGF receptor-1; 
VEGF, vascular endothelial growth factor A; Wnt5a, wingless-type MMTV integration site family, 
member 5A. 
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FIGURE LEGENDS 
FIGURE 1. Glrx overexpression attenuates EC-migration and network formation, as well as aortic 
sprouting. A, Western blot analysis of human Glrx transgene or endogenous Glrx in WT and TG mouse 
microvascular ECs (mEC). B, Representative and C, quantitative blinded scoring of EC network 
formation in WT and TG mEC seeded onto Matrigel in the presence and absence of VEGF (50ng/ml) 
(n=6, * P<0.05). D, Representative and E, percentage wound closure of WT and TG mECs after 18h 
VEGF (50ng/ml) treatment, measured at 4-pre-determined locations (n=3, * P<0.05). F, Representative 
and G, quantitative assessment of sprouting of ECs from isolated WT and TG aortae after 6 days cultured 
on Matrigel in DMEM 2% FBS with and without VEGF (50ng/ml) (n=4, * P<0.05).  
FIGURE 2. Glrx attenuates EC function via the anti-angiogenic receptor, soluble FLT. mRNA levels 
of A, sFlt and B, mFlt isoforms in WT and TG mouse microvascular endothelial cells (mEC) under 
normoxia and hypoxia (0.5% Oxygen, 20h,  n=5, * P<0.05). C, ELISA; sFLT level in the media from WT 
and TG mEC in normoxic and hypoxic (0.5% Oxygen, 20h) conditions (n=5, * P<0.05, # P<0.01). D, sFlt 
mRNA expression by qPCR in human microvascular endothelial cells (hEC) treated with siRNA to sFlt 
(si-sFlt) or off-target scramble RNA (scr) after AdGlrx or AdLacZ infection (n=3, * P<0.05). E, 
Proliferation of hEC in the presence and absence of VEGF (50ng/ml, 24h) after adenoviral Glrx or LacZ 
overexpression and subsequent sFlt knockdown by siRNA compared to scr control (n=4, * P<0.05). F, 
Quantitative data and G, representative images of AdGlrx and AdLacZ treated hEC after 18h VEGF 
(50ng/ml) treatment, measured at 4-pre-determined locations. The effects of si-sFlt are shown compared 
to scr (n=5, * P<0.05). H, Quantitative measurement and I, representative images of EC network 
formation in AdGlrx and AdLacZ treated hEC with siRNA sFLT or scr control in the presence of VEGF 
(50ng/ml) (n=6, * P<0.05, *** P<0.001). 
FIGURE 3: Glrx causes a Wnt5a-dependent increase in sFLT expression in human ECs. qRT-PCR 
analysis for A, Wnt5a and B, Ror2 mRNA in EC isolated from WT and TG mice (n=5, * P<0.05). qRT-
PCR analysis of C, sFlt and D, mFlt in human microvascular endothelial cells (hEC) treated with 
rhWnt5a (100 ng/ml) over time indicated (n=5, * P<0.05). E, Representative images  and F, quantitative 
assessment of hEC network formation in the presence and absence of Wnt5a (100 ng/ml, 24h), with and 
without VEGF treatment (50 ng/ml, 18h, n=4, * P<0.05). qRT-PCR for G, Wnt5a and H, sFlt in hECs 
overexpressing Glrx or LacZ by adenovirus treatment. (n=6, * P<0.05). I, sFlt mRNA expression in 
AdLacZ and AdGlrx treated hEC in the presence and absence of Box5 (Wnt5a antagonist, 100 µM, 24h. 
n=6, * P<0.05). 
FIGURE 4: Glrx overexpression attenuates revascularization, limb motor function, and capillary 
density after hind limb ischemia (HLI) surgery. A, The structure of the human Glrx transgene driven 
by the -actin promoter, CAP: transcriptional initiation site of the human -actin gene. B, Western blot 
analysis of human Glrx transgene (hGlrx) and endogenous Glrx (mGlrx) in WT and TG gastrocnemius 
muscle. C, Glrx activity in heart and skeletal muscle homogenate from WT and Glrx TG mice.  Activity 
was normalized to protein weight.  (n=5. * =P<0.05).  D, Quantitative serial assessment of LASER 
Doppler measuring blood flow recovery to the plantar aspect of WT and TG paws post hind-limb 
ischemia surgery (n=15, * P<0.05).  E, representative LASER Doppler images obtained post-surgery and 
on day 14. F, representative images of ischemic paws from WT and TG mice 14 days after surgery. G, 
Scoring of motor function of ischemic limb from WT and TG mice on day 14 (n=12, * P<0.05). H, 
Duration of time on treadmill 10 days post-HLI surgery running at 5 m/min with 5 m/min increments 
every 5 minutes (n=6, * P<0.05). I, Representative images (scale 100µm) and J, quantitative analysis of 
isolectin B4 staining for capillaries in non-ischemic (NI) and ischemic (ISC) gastrocnemius muscle in WT 
and TG mice 14-days post-HLI surgery (n=5, * P<0.05). 
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FIGURE 5: Up-regulation of the anti-angiogenic receptor, soluble FLT and Wnt5a in Glrx 
overexpressing mice post HLI. mRNA expression of A, soluble and B, membrane bound Flt isoforms, 
C, VEGF and D, VEGFR2 in non-ischemic (NI) and ischemic (ISC) gastrocnemius muscles from WT and 
Glrx TG mice 14 days post-HLI (n=6, P<0.05). ELISA for E, sFLT1 and F, VEGF in plasma from WT 
and Glrx TG mice at 4 days (n=6) and 14 days (n=12) post-HLI (* P<0.05). G, Representative 
immunoblot of Wnt5a in non- and ischemic gastrocnemius muscle normalized to tubulin. 
FIGURE 6. Glrx decreases p65-glutathione adducts in ischemic muscle and endothelial cells. A-D, 
Biotin switch assay showing the biotin labeled S-glutathionylated cysteines within p65 (pull down) in A, 
WT and Glrx TG non-ischemic (NI) and ischemic (ISC) muscle 4-days post-HLI, and in C, hEC 
overexpressing Glrx or LacZ under normoxic or hypoxic (0.1% 24h) conditions with (B&D) respective 
quantification of glutathione adducts normalized to p65-input, samples prior to incubation with 
streptavidin beads (n=3-4, * P<0.05, ** P<0.01). 
FIGURE 7. Glrx enhances Wnt5a and sFLT in a NF-kB-dependent manner. A, NF-kB activity 
measured by luciferase reporter assay in the presence and absence of TNF (50 ng/ml, 4h). NF-kB-
reporter activity normalized to the co-transfected renilla-luciferase reporter in WT and Glrx TG mEC (* 
P<0.05, *** P<0.001; n=3). B, Wnt5a mRNA expression in AdGlrx infected hEC incubated with and 
without MG132 (1 µM, 24h; P<0.05, n=4). C-G, siRNA knockdown of p65 NFB subunit on Glrx 
overexpressing hEC. C, Immunoblot for p65 and -actin of hEC treated with a concentration range (10, 
25, 50, 100nM, 72h) of siRNA to p65 or equivalent off-target control (scr). D, hEC mRNA for E-selectin 
after p65 knockdown (25nM) in the presence and absence of TNFα (40ng/ml) stimulation. E, IL-6, F, 
Wnt5a, G, sFlt, and H, VEGFR2 mRNA expression assessed by qRT-PCR after p65-siRNA or scrambled 
control treatment in AdGlrx or AdLacZ infected hEC (P<0.05, n=6). 
FIGURE 8. Elevated Wnt5a expression promotes sFlt induction in the Glrx up-regulated EC. 
Summary of data in this study is shown. Glrx overexpression increased Wnt5a and sFlt mRNA and 
secretion of sFlt from EC, thus VEGF-induced vascularization is impaired. NF-kB inactivation (siRNA) 
suppressed Glrx-induced sFlt and Wnt5a. Wnt5a antagonist (BOX5) inhibited Glrx-induced sFlt. 
Exogenous Wnt5a increased sFlt in EC. Inhibiting sFlt (siRNA) improved angiogenic phenotype of EC 
overexpressing Glrx. 
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